Title |
Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event
|
---|---|
Published in |
BMC Cancer, July 2016
|
DOI | 10.1186/s12885-016-2434-7 |
Pubmed ID | |
Authors |
Christophe Maritaz, Carole Metz, Nabil Baba-Hamed, Méryam Jardin-Szucs, Gaël Deplanque |
Abstract |
Cetuximab is a commonly used antibody agent in the treatment of colorectal or head and neck cancer. Although it is generally well tolerated in most patients, cetuximab has been associated with some rare but serious adverse events. Aseptic meningitis is one such distinctly uncommon adverse drug reaction. We present the case of a middle-aged Caucasian patient, who presented with fever and headache within a few hours of starting cetuximab therapy and was diagnosed with cetuximab-induced aseptic meningitis after a complete workup. To our knowledge, this is the ninth case of cetuximab-induced aseptic meningitis reported in literature. Because of a nonspecific clinical presentation, this adverse drug reaction can be easily misdiagnosed. It is important to increase awareness of this potentially severe reaction among oncologists. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 4 | 21% |
Other | 2 | 11% |
Student > Doctoral Student | 2 | 11% |
Lecturer > Senior Lecturer | 1 | 5% |
Unspecified | 1 | 5% |
Other | 3 | 16% |
Unknown | 6 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 26% |
Neuroscience | 2 | 11% |
Unspecified | 1 | 5% |
Economics, Econometrics and Finance | 1 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Other | 2 | 11% |
Unknown | 7 | 37% |